🇺🇸 FDA
Pipeline program

Losmapimod oral tablet

FIS-002-2019

Phase 2 small_molecule completed

Quick answer

Losmapimod oral tablet for Facioscapulohumeral Muscular Dystrophy (FSHD) is a Phase 2 program (small_molecule) at Fulcrum Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Fulcrum Therapeutics
Indication
Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials